SEARCH

SEARCH BY CITATION

References

  • 1
    Lebrec D, Nouel O, Corbic M, Benhamou JP. Propranolol–a medical treatment for portal hypertension? Lancet 1980; 2: 1802.
  • 2
    Feu F, Garcia-Pagan JC, Bosch J, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995; 346: 10569.
  • 3
    Groszmann RJ, Bosch J, Grace ND, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990; 99: 14017.
  • 4
    Gatta A, Bolognesi M, Merkel C, et al. Long-term effects of beta-adrenergic blockade with nadolol on hepatic and renal haemodynamics and function in cirrhotics. Clin Physiol 1987; 7: 37787.
  • 5
    Vorobioff J, Picabea E, Villavicencio R, et al. Acute and chronic hemodynamic effects of propranolol in unselected cirrhotic patients. Hepatology 1987; 7: 64853.
  • 6
    Merkel C, Sacerdoti D, Bolognesi M, et al. Effect of chronic treatment with nadolol plus isosorbide mononitrate on liver blood flow and liver metabolic activity in cirrhosis. Eur J Gastroenterol Hepatol 1999; 11: 12215.
  • 7
    Gluud LL, Langholz E, Krag A. Meta-analysis: isosorbide-mononitrate alone or with either beta-blockers or endoscopic therapy for the management of oesophageal varices. Aliment Pharmacol Ther 2010; 32: 85971.
  • 8
    Gluud LL, Krag A. Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults. Cochrane Database Syst Rev 2012; 8: CD004544.
  • 9
    Thiele M, Krag A, Rohde U, Gluud LL. Meta-analysis: banding ligation and medical interventions for the prevention of rebleeding from oesophageal varices. Aliment Pharmacol Ther 2012; 35: 115565.
  • 10
    Banares R, Moitinho E, Matilla A, et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology 2002; 36: 136773.
  • 11
    Tripathi D, Ferguson JW, Kochar N, et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology 2009; 50: 82533.
  • 12
    Lo GH, Chen WC, Wang HM, Yu HC. Randomized, controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding. J Gastroenterol Hepatol 2012; 27: 16817.
  • 13
    Augustin S, Gonzalez A, Badia L, et al. Long-term follow-up of hemodynamic responders to pharmacological therapy after variceal bleeding. Hepatology 2012; 56: 70614.
  • 14
    Reiberger T, Ulbrich G, Ferlitsch A, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut 2013; 62: 163441.
  • 15
    Senzolo M, Cholongitas E, Burra P, et al. Beta-blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int 2009; 29: 118993.
  • 16
    Serste T, Melot C, Francoz C, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010; 52: 101722.
  • 17
    Serste T, Francoz C, Durand F, et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol 2011; 55: 7949.
  • 18
    Newby DE, Hayes PC. Hyperdynamic circulation in liver cirrhosis: not peripheral vasodilatation but ‘splanchnic steal’. QJM 2002; 95: 82730.
  • 19
    Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002; 35: 47891.
  • 20
    Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology 2004; 39: 2802.
  • 21
    Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005; 353: 225461.
  • 22
    Ohnishi K, Nakayama T, Saito M, et al. Effects of propranolol on portal hemodynamics in patients with chronic liver disease. Am J Gastroenterol 1985; 80: 1325.
  • 23
    Mastai R, Bosch J, Navasa M, et al. Effects of alpha-adrenergic stimulation and beta-adrenergic blockade on azygos blood flow and splanchnic haemodynamics in patients with cirrhosis. J Hepatol 1987; 4: 719.
  • 24
    Pascal JP, Cales P. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med 1987; 317: 85661.
  • 25
    Tripathi D, Hayes PC. Review article: a drug therapy for the prevention of variceal haemorrhage. Aliment Pharmacol Ther 2001; 15: 291310.
  • 26
    Merkel C, Bolognesi M, Sacerdoti D, et al. Disagreement between acute and chronic haemodynamic effects of nadolol in cirrhosis: a pathophysiological interpretation. Aliment Pharmacol Ther 2005; 22: 4339.
  • 27
    Sharma P, Kumar A, Jha S, et al. The haemodynamic response to propranolol in cirrhosis with arterial hypertension: a comparative analysis with normotensive cirrhotic patients. Aliment Pharmacol Ther 2010; 32: 10512.
  • 28
    Brochard U. Pharmacological properties of beta-adrenoceptor blocking drugs. J Clin Basic Cardiol 1998; 1: 59.
  • 29
    Escorsell A, Ferayorni L, Bosch J, et al. The portal pressure response to beta-blockade is greater in cirrhotic patients without varices than in those with varices. Gastroenterology 1997; 112: 20126.
  • 30
    Mills PR, Rae AP, Farah DA, et al. Comparison of three adrenoreceptor blocking agents in patients with cirrhosis and portal hypertension. Gut 1984; 25: 738.
  • 31
    Westaby D, Bihari DJ, Gimson AE, Crossley IR, Williams R. Selective and non-selective beta receptor blockade in the reduction of portal pressure in patients with cirrhosis and portal hypertension. Gut 1984; 25: 1214.
  • 32
    Westaby D, Melia WM, Macdougall BR, et al. B1 selective adrenoreceptor blockade for the long term management of variceal bleeding. A prospective randomised trial to compare oral metoprolol with injection sclerotherapy in cirrhosis. Gut 1985; 26: 4215.
  • 33
    Braillon A, Cales P, Lebrec D. Comparison of the short-term effects of mepindolol and propranolol on splanchnic and systemic haemodynamics in patients with cirrhosis. Int J Clin Pharmacol Res 1985; 5: 2238.
  • 34
    Bihari D, Westaby D, Gimson A, et al. Reductions in portal pressure by selective beta 2-adrenoceptor blockade in patients with cirrhosis and portal hypertension. Br J Clin Pharmacol 1984; 17: 7537.
  • 35
    Dulin B, Abraham WT. Pharmacology of carvedilol. Am J Cardiol 2004; 93: 3B6B.
  • 36
    Akbas H, Ozden M, Kanko M, et al. Protective antioxidant effects of carvedilol in a rat model of ischaemia-reperfusion injury. J Int Med Res 2005; 33: 52836.
  • 37
    Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292: 222736.
  • 38
    Hamdy N, El Demerdash E. New therapeutic aspect for carvedilol: antifibrotic effects of carvedilol in chronic carbon tetrachloride-induced liver damage. Toxicol Appl Pharmacol 2012; 261: 2929.
  • 39
    Tripathi D, Therapondos G, Lui HF, Stanley AJ, Hayes PC. Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension. Aliment Pharmacol Ther 2002; 16: 37380.
  • 40
    Banares R, Moitinho E, Piqueras B, et al. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology 1999; 30: 7983.
  • 41
    De BK, Das D, Sen S, et al. Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics. J Gastroenterol Hepatol 2002; 17: 1839.
  • 42
    Hobolth L, Moller S, Gronbaek H, et al. Carvedilol or propranolol in portal hypertension? A randomized comparison Scand J Gastroenterol 2012; 47: 46774.
  • 43
    Plevris JN, Elliot R, Mills PR, et al. Effect of propranolol on prevention of first variceal bleed and survival in patients with chronic liver disease. Aliment Pharmacol Ther 1994; 8: 6370.
  • 44
    Cales P, Oberti F, Payen JL, et al. Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis: a randomized trial. French-Speaking Club for the Study of Portal Hypertension. Eur J Gastroenterol Hepatol 1999; 11: 7415.
  • 45
    Merkel C, Marin R, Angeli P, et al. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology 2004; 127: 47684.
  • 46
    de Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010; 53: 7628.
  • 47
    Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 2010; 362: 82332.
  • 48
    Cheng JW, Zhu L, Gu MJ, Song ZM. Meta analysis of propranolol effects on gastrointestinal hemorrhage in cirrhotic patients. World J Gastroenterol 2003; 9: 18369.
  • 49
    Angelico M, Carli L, Piat C, Gentile S, Capocaccia L. Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis. Gastroenterology 1997; 113: 16329.
  • 50
    Borroni G, Salerno F, Cazzaniga M, et al. Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites. J Hepatol 2002; 37: 31521.
  • 51
    Garcia-Pagan JC, Morillas R, Banares R, et al. Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT. Hepatology 2003; 37: 12606.
  • 52
    Merkel C, Marin R, Sacerdoti D, et al. Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000; 31: 3249.
  • 53
    Avgerinos A, Armonis A, Manolakopoulos S, et al. Endoscopic sclerotherapy plus propranolol versus propranolol alone in the primary prevention of bleeding in high risk cirrhotic patients with esophageal varices: a prospective multicenter randomized trial. Gastrointest Endosc 2000; 51: 6528.
  • 54
    Gotoh Y, Iwakiri R, Sakata Y, et al. Evaluation of endoscopic variceal ligation in prophylactic therapy for bleeding of oesophageal varices: a prospective, controlled trial compared with endoscopic injection sclerotherapy. J Gastroenterol Hepatol 1999; 14: 2414.
  • 55
    Masumoto H, Toyonaga A, Oho K, Iwao T, Tanikawa K. Ligation plus low-volume sclerotherapy for high-risk esophageal varices: comparisons with ligation therapy or sclerotherapy alone. J Gastroenterol 1998; 33: 15.
  • 56
    Lo GH, Chen WC, Chen MH, et al. Endoscopic ligation vs. nadolol in the prevention of first variceal bleeding in patients with cirrhosis. Gastrointest Endosc 2004; 59: 3338.
  • 57
    Lui HF, Stanley AJ, Forrest EH, et al. Primary prophylaxis of variceal hemorrhage: A randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate. Gastroenterology 2002; 123: 73544.
  • 58
    Funakoshi N, Duny Y, Valats JC, et al. Meta-analysis: beta-blockers versus banding ligation for primary prophylaxis of esophageal variceal bleeding. Ann Hepatol 2012; 11: 36983.
  • 59
    Shah HA, Rauf J, Azam Z, et al. Randomized controlled trial of Carvedilol vs Variceal band ligation in the primary prophylaxis of variceal haemorrhage. Hepatology 2012; 56: 272A.
  • 60
    Albillos A, Banares R, Gonzalez M, et al. Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis. Am J Gastroenterol 2007; 102: 111626.
    Direct Link:
  • 61
    Villanueva C, Aracil C, Colomo A, et al. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding. Gastroenterology 2009; 137: 11928.
  • 62
    La Mura V., Abraldes JG., Raffa S., et al. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. J Hepatol 2009; 51: 27987.
  • 63
    Bernard B, Lebrec D, Mathurin P, Opolon P, Poynard T. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology 1997; 25: 6370.
  • 64
    Lo GH, Chen WC, Lin CK, et al. Improved survival in patients receiving medical therapy as compared with banding ligation for the prevention of esophageal variceal rebleeding. Hepatology 2008; 48: 5807.
  • 65
    Reiberger T, Ferlitsch A, Payer BA, et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol 2013; 58: 91121.
  • 66
    Smith L, Dickson S, Hayes PC, et al. Multicentre Randomised Controlled Study Comparing Carvedilol With Endoscopic Band Ligation In The Prevention Of Variceal Rebleeding. J Hepatol 2013; 58: S255.
  • 67
    Copaci I, Micu L, Mindrut E, Voiculescu M. Endoscopic variceal ligation alone versus endoscopic variceal ligation plus carvedilol in variceal bleeding prophylaxis in cirrhotic patients. J Hepatol 2012; 56: S2612.
  • 68
    Lin HC, Yang YY, Hou MC, et al. Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis. Am J Gastroenterol 2004; 99: 19538.
  • 69
    Chen CY, Sheu MZ, Su SY. Prophylactic endoscopic variceal ligation EVL) with multiple band ligator for esophageal varices. Gastroenterology 1998; 114: A1224.
  • 70
    Sarin SK, Lamba GS, Kumar M, Misra A, Murthy NS. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. N Engl J Med 1999; 340: 98893.
  • 71
    De BK, Ghoshal UC, Das T, Santra A, Biswas PK. Endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleed: preliminary report of a randomized controlled trial. J Gastroenterol Hepatol 1999; 14: 2204.
  • 72
    De la Mora JD, Farca B, Uribe M, de Hoyos-Garza A. Ligation vs. propranolol for primary prophylaxis of variceal bleeding using a multiple band ligator and objective measurements of treatment adequacy: preliminary results [Abstract]. Gastroenterology 2000; 118: A14345.
  • 73
    Song IH, Shin JW, Kim IH, et al. A prospective randomized trial between the prophylactic endoscopic variceal ligation and propranolol administration for prevention of first bleeding in cirrhotic patients with high-risk esophageal varices [Abstract]. J Hepatol 2000; 32(Suppl. 2): 41.
  • 74
    Gheorghe C, Gheorghe L, Vaden R, Hrehoret D, Popescu I. Prophylactic banding ligation of high risk esophageal varices in patients on the waiting list for liver transplantation: an interim analysis [Abstract]. J Hepatol 2002; 36(Suppl. 1): 38.
  • 75
    Abulfutuh MR, Morsby M, Solyman AEG, et al. Study of variceal band ligation, propranolol, and isosorbide mononitrate in the prevention of the first variceal bleeding. Gastroenterology 2003; 124: A780.
  • 76
    Schepke M, Kleber G, Nurnberg D, et al. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2004; 40: 6572.
  • 77
    Jutabha R, Jensen DM, Martin P, et al. Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices. Gastroenterology 2005; 128: 87081.
  • 78
    Thuluvath PJ, Maheshwari A, Jagannath S, Arepally A. A randomized controlled trial of beta-blockers versus endoscopic band ligation for primary prophylaxis: a large sample size is required to show a difference in bleeding rates. Dig Dis Sci 2005; 50: 40710.
  • 79
    Psilopoulos D, Galanis P, Goulas S, et al. Endoscopic variceal ligation vs. propranolol for prevention of first variceal bleeding: a randomized controlled trial. Eur J Gastroenterol Hepatol 2005; 17: 11117.
  • 80
    Abdelfattah MH, Rashed MA, Elfakhry AA, Soliman MA, Shiha GE. Endoscopic variceal ligation versus pharmacologic treatment for primary prophylaxis of variceal bleeding: A randomised study. J Hepatol 2006; 44: S83.
  • 81
    Lay CS, Tsai YT, Lee FY, et al. Endoscopic variceal ligation versus propranolol in prophylaxis of first variceal bleeding in patients with cirrhosis. J Gastroenterol Hepatol 2006; 21: 4139.
  • 82
    Norberto L, Polese L, Cillo U, et al. A randomized study comparing ligation with propranolol for primary prophylaxis of variceal bleeding in candidates for liver transplantation. Liver Transpl 2007; 13: 12728.
  • 83
    Perez-Ayuso RM, Valderrama S, Espinoza M, et al. Endoscopic band ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhotic patients with high risk esophageal varices. Ann Hepatol 2010; 9: 1522.
  • 84
    Drastich P, Lata J, Petrtyl J, et al. Endoscopic variceal band ligation compared with propranolol for prophylaxis of first variceal bleeding. Ann Hepatol 2011; 10: 1429.
  • 85
    Agrawal SR, Gupta R, Murthy NS, Sarin SK. Comparable efficacy of propranolol plus isosorbide mononitrate and endoscopic variceal ligation in prevention of variceal rebleed. J Hepatol 2002; 36: 1789.
  • 86
    Villanueva C, Minana J, Ortiz J, et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001; 345: 64755.
  • 87
    Patch D, Sabin CA, Goulis J, et al. A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology 2002; 123: 10139.
  • 88
    Sarin SK, Wadhawan M, Gupta R, Shahi H. Evaluation of endoscopic variceal ligation (EVL) versus propanolol plus isosorbide mononitrate/nadolol (ISMN) in the prevention of variceal rebleeding: comparison of cirrhotic and noncirrhotic patients. Dig Dis Sci 2005; 50: 153847.
  • 89
    Shiha G, Menesy A, Seef S, et al. Endoscopic ligation compared with propranolol and combined isosorbide mononitrates (ISMM) and propranolol to prevent recurrent variceal bleeding: A prospective randomised trial. Gut 2005; 54: A6.
  • 90
    Abdel-Rahim AY, Abdel-Ghany MS, El Kholy B. Band ligation alone versus band ligation and propranolol in the management of bleeding oesophageal varices. Am J Gastroenterol 2000; 95: 2442.
    Direct Link:
  • 91
    Lo GH, Lai KH, Cheng JS, et al. Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial. Hepatology 2000; 32: 4615.
  • 92
    Lo GH, Lai KH, Cheng JS, et al. The effects of endoscopic variceal ligation and propranolol on portal hypertensive gastropathy: a prospective, controlled trial. Gastrointest Endosc 2001; 53: 57984.
  • 93
    Sollano JD, Chan MM, Ismael AE, Babaran RP, Lim EL. Propranolol prevents rebleeding after variceal ligation. Gastrointest Endosc 2001; 53: AB143.
  • 94
    de la Peña J, Brullet E, Sanchez-Hernandez E, et al. Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial. Hepatology 2005; 41: 5728.
  • 95
    Lo GH, Chen WC, Chan HH, et al. A randomized, controlled trial of banding ligation plus drug therapy versus drug therapy alone in the prevention of esophageal variceal rebleeding. J Gastroenterol Hepatol 2009; 24: 9827.
  • 96
    Garcia-Pagan JC, Villanueva C, Albillos A, et al. Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomised controlled trial. Gut 2009; 58: 114450.
  • 97
    Ahmad I, Khan AA, Alam A, et al. Propranolol, isosorbide mononitrate and endoscopic band ligation - alone or in varying combinations for the prevention of esophageal variceal rebleeding. J Coll Physicians Surg Pak 2009; 19: 2836.
  • 98
    Kumar A, Jha SK, Sharma P, et al. Addition of propranolol and isosorbide mononitrate to endoscopic variceal ligation does not reduce variceal rebleeding incidence. Gastroenterology 2009; 137: 892901, 901.